-
1.发明公开MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING ALTERNATIVE FUNCTION TO FUNCTION OF BLOOD COAGULATION FACTOR VIII 有权多用途抗生素MLEEZIFISCHES抗生素MLEEKINL MIT EINER BLUTGERINNUNGSFAKTOR-VIII-WECHSELFUNKTION
公开(公告)号：EP2644698A4
公开(公告)日：2015-07-01
申请号：EP11842145
申请日：2011-11-17
发明人： IGAWA TOMOYUKI , SAMPEI ZENJIRO , KOJIMA TETSUO , SOEDA TETSUHIRO , MUTO ATSUSHI , KITAZAWA TAKEHISA , NISHIDA YUKIKO , IMAI CHIFUMI , SUZUKI TSUKASA , YOSHIHASHI KAZUTAKA
CPC分类号： C07K16/40 , C07K16/36 , C07K2317/31 , C07K2317/51 , C07K2317/56 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/94
摘要： Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.
摘要翻译： 各种双特异性抗体特异性结合血液凝固因子IX /活化血液凝固因子IX和血液凝固因子X，并功能代替血液凝固因子VIII的辅因子功能，即促进凝血因子X活化的功能 活化血液凝固因子IX。 从这些抗体中，成功发现了具有高功能取代凝血因子VIII活性的多特异性抗原结合分子。
-
2.发明公开
公开(公告)号：EP3199554A4
公开(公告)日：2018-07-18
申请号：EP15843808
申请日：2015-09-24
IPC分类号： C07K16/42 , C07K16/00 , C07K16/36 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12P21/08
摘要： The present inventors attempted to produce antibodies that neutralize the activity of a substance having an activity of functionally substituting for FVIII to be used for the method of measuring the reactivity of FVIII in the presence of a substance having an activity of functionally substituting for FVIII. As a result, the inventors discovered that by using the produced antibodies, FVIII activity in the plasma of a hemophilia A patient can be evaluated accurately by one-stage clotting assay based on APTT, and also that FVIII inhibitor titer in the plasma of a hemophilia A patient carrying a FVIII inhibitor can be evaluated accurately by Bethesda assay based on APTT.
-
3.发明公开TREATMENT FOR HEMORRHAGIC DISEASES BY ANTI-PROTEIN-C ANTIBODY 审中-公开BEHANDLUNG VONHÄMORRHAGISCHENERKRANKUNGEN DURCH抗蛋白-C抗体
公开(公告)号：EP3047857A4
公开(公告)日：2017-08-09
申请号：EP14845545
申请日：2014-09-19
IPC分类号： A61K39/395 , A61K45/00 , A61P7/04 , C07K16/18
CPC分类号： C07K16/40 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/76 , A61K2300/00
摘要： The present inventors have completed the present invention by finding that an excellent anticoagulation inhibitory effect is obtained by the administration of an agent inhibiting the activation of protein C.
摘要翻译： 本发明人通过发现通过施用抑制蛋白质C活化的试剂获得优异的抗凝血抑制作用，从而完成了本发明。
-
-
搜索结果
3 条记录 (耗时 0.009 秒)
